BioSpace News Archive

More than 100,000 CytoSorb treatments delivered, tens of thousands of patients treated, and many lives saved

CASI Pharmaceuticals, Inc., a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced the Company will host a conference call reviewing the second quarter highlights at 4:30 p.m. ET on Monday, August 10th, 2020.

Spectrum Pharmaceuticals a biopharmaceutical company focused on novel and targeted oncology therapies, announced it will host a conference call to discuss the second quarter 2020 financial results and provide a corporate update on Monday, August 10, 2020 at 4:30 p.m. Eastern/1:30 p.m. Pacific.

Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference 2020 on August 10, 2020 at 1:00 p.m. ET.

Veteran executive brings proven record of operational excellence in building biotech companies

IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines to fight against infectious diseases including COVID-19, announced today that it will hold a conference call and webcast on Wednesday, August 12, 2020 at 8:00 a.m. ET to discuss the company’s second quarter 2020 financial and operational results.

Humanigen, Inc. announced the appointment of Timothy E. Morris to the newly created role of Chief Operating Officer and Chief Financial Officer, effective immediately, reporting to Dr. Cameron Durrant, Chief Executive Officer.

Humanigen, Inc., announced that the Company will host an investor call and webcast to discuss the National Institute of Health’s selection of lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody drug candidate, as an agent to be evaluated in the NIAID-sponsored Big Effect Trial in hospitalized patients with COVID-19.

Company CEO Recognized for Launching US Outpost for Korea’s Samyang Pharmaceuticals and Innovative Leadership, Ability to Attract R&D Partnerships

Increased fiscal 2021 Adjusted Earnings per diluted share guidance range to $14.70 to $15.50, from the previous range of $13.95 to $14.75.